Telomir Pharmaceuticals, Inc. Common Stock (TELO) Financials
TELO Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 5.4 million | 332424 |
| March 31, 2026 | 5.8 million | 827310 |
| Dec. 31, 2025 | 7.3 million | 1.4 million |
| Sept. 30, 2025 | 7.4 million | 422807 |
TELO Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -1.0 million | 238537 |
| March 31, 2026 | -1.8 million | 39803 |
| Dec. 31, 2025 | -1.2 million | 832051 |
| Sept. 30, 2025 | -927264 | -741858 |
TELO Net Income
No data available :(
TELO Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 5.2 million | - | - |
| March 31, 2026 | 5.6 million | - | - |
| Dec. 31, 2025 | 7.3 million | - | - |
| Sept. 30, 2025 | 7.3 million | - | - |
TELO Shares Outstanding
TELO Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | - | 444674 | 1.3 million | - |
| March 31, 2026 | - | 467797 | 573539 | - |
| Dec. 31, 2025 | 3 | 1.3 million | 838472 | - |
| Sept. 30, 2025 | 5 | 759525 | 386951 | - |
TELO Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
TELO
Price: $1.05
52 week price:
Earnings Per Share: -1.11 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 81.2 million